• Sun, Jan. 1, 6:27 AM
    • Continuing our series of surfacing 2016 stinkers, here are the 25 Russell 2000 stocks that imploded in 2016. Further down, you'll find the 25 worst stocks excluding pharma.
    • Ophthotech (NASDAQ:OPHT) -94%
    • Galena Biopharma (NASDAQ:GALE) -93%
    • Cempra (NASDAQ:CEMP) -91%
    • Toaki Pharma (NASDAQ:TKAI) -89%
    • Anthera Pharma (NASDAQ:ANTH) -86%
    • Adeptus Health (NYSE:ADPT) -86%
    • CytRx (NASDAQ:CYTR) -86%
    • Novavax (NASDAQ:NVAX) -85%
    • Mirati Therapeutics (NASDAQ:MRTX) -85%
    • ImmunoGen (NASDAQ:IMGN) -85%
    • OvaScience (NASDAQ:OVAS) -84%
    • Avinger (NASDAQ:AVGR) -84%
    • Dynavax (NASDAQ:DVAX) -84%
    • Infinity Pharma (NASDAQ:INFI) -83%
    • Tandem Diabetes (NASDAQ:TNDM) -82%
    • First NBC Bank (NASDAQ:FNBC) -80%
    • Corindus Vascular Robotics (NYSEMKT:CVRS) -78%
    • Celldex Therapeutics (NASDAQ:CLDX) -77%
    • Cobalt International Energy (NYSE:CIE) -77%
    • Arrowhead Pharma (NASDAQ:ARWR) -75%
    • Community Health Systems (NYSE:CYH) -74%
    • Regulus Therapeutics (NASDAQ:RGLS) -74%
    • Vivent Solar (NYSE:VSLR) -73%
    • Immune Design (NASDAQ:IMDZ) -73%
    • Intra-Cellular (NASDAQ:ITCI) -72%
    • Now here's the same list after filtering out pharma, biotech and healthcare stocks:
    • First NBC Bank (FNBC) -80%
    • Cobalt International Energy (CIE) -77%
    • Vivint Solar (VSLR) -73%
    • MDC Partners (NASDAQ:MDCA) -69%
    • Walter Investment Management (NYSEMKT:WAC) -67%
    • FuelCell Energy (NASDAQ:FCEL) -65%
    • Teekay Tankers (NYSE:TNK) -64%
    • Diplomat Pharmacy (NYSE:DPLO) -63%
    • GNC Holdings (NYSE:GNC) -63%
    • Hortonworks (NASDAQ:HDP) -62%
    • Restoration Hardware (NYSE:RH) -61%
    • CPI Card Group (NASDAQ:PMTS) -60%
    • Power Solutions (NASDAQ:PSIX) -59%
    • AgroFresh Solutions (NASDAQ:AGFS) -58%
    • Noodles & Co. (NASDAQ:NDLS) -58%
    • NII Holdings (NASDAQ:NIHD) -58%
    • On Deck Capital (NYSE:ONDK) -55%
    • Rubicon Project (NYSE:RUBI) -55%
    • Sunrun (NASDAQ:RUN) -55%
    • Sears Holdings (NASDAQ:SHLD) -55%
    • Abercrombie & Fitch (NYSE:ANF) -54%
    • TerraVia Holdings (NASDAQ:TVIA) -54%
    • Infinera (NASDAQ:INFN) -53%
    • Cogint (NASDAQ:COGT) -53%
    Sun, Jan. 1, 6:27 AM | 86 Comments
  • Dec. 13, 2016, 9:27 AM
    • CytRx (NASDAQ:CYTR) is off 21% premarket on robust volume in response to its announcement of an $8.1M direct offering of common stock at $0.42 a share. Closing date is December 16.
    • Net proceeds of ~$7.4M will fund working capital and general corporate purposes.
    Dec. 13, 2016, 9:27 AM | 11 Comments
  • Nov. 29, 2016, 7:18 AM
    • Undeterred by the failure of a Phase 3 clinical trial assessing lead product candidate aldoxorubicin in patients soft tissue sarcoma (STS), CytRx (NASDAQ:CYTR) reanalyzed the data and found a subset of patients that experienced a treatment effect over and above investigator's choice of therapy.
    • 246 patients with leiomyosarcoma and liposarcoma, the most common types of STS, treated with aldoxorubicin showed a statistically significant improvement in progression-free survival (PFS) compared to investigator's choice with a 38% reduction in the risk of cancer progression (hazard ratio = 0.62).
    • North American patients also experienced a statistically valid improvement in PFS with lower risk of cancer progression, although its is doubtful that parsing cancer patients according to geography will pass muster with the FDA.
    • The company says it plans to file a New Drug Application (NDA) in the U.S. in 2017. The results will be submitted for presentation at an upcoming scientific conference.
    • Management will host a conference call this morning at 8:30 am ET to discuss the data.
    • Previously: CytRx's lead product candidate shows mixed results in late-stage study; shares plummet 56% after hours (July 11)
    Nov. 29, 2016, 7:18 AM | 94 Comments
  • Nov. 11, 2016, 10:49 AM
    • Interim data from a Phase 1b/2 study assessing CytRx's (CYTR +4.7%) aldoxorubicin, in combination with the chemo agent ifosamide (together with mesna to mitigate the side effects of ifosamide), for the treatment of patients with advanced sarcomas showed a positive treatment effect. The results were presented at the 2016 Annual Meeting of the Connective Tissue Oncology Society in Lisbon, Portugal.
    • In 36 evaluable patients receiving either 170 mg/m2 (n=7) or 250 mg/m2 (n=29) of aldoxorubicin plus ifosamide/mensa, 39% experienced a partial response (n=14/36) while 58% (n=21/36) had stable disease, implying a disease control rate of 97% (n=35/36). One patient progressed. Median progression-free survival has not been reached.
    • The most common Grade 3 (severe) or Grade 4 (life-threatening) adverse events were neutropenia (71%), anemia (54%), thrombocytopenia (17%) and febrile neutropenia (14%).
    • The trial has been expanded to allow for additional enrollment at the 250 mg/m2 dose. According to ClinicalTrials.gov, the estimated study completion date is December 2018.
    • Aldoxorubicin is a conjugate of the chemo agent doxorubicin and an acid-sensitive linker that binds to circulating albumin. This supposedly drives greater uptake in the tumor which enables higher dosing without the collateral damage to healthy tissue.
    Nov. 11, 2016, 10:49 AM | 12 Comments
  • Nov. 9, 2016, 9:07 AM
    • CytRx (NASDAQ:CYTR): Q3 EPS of -$0.13 in-line.
    • Cash and cash equivalents of $58.88M.
    • Press Release
    Nov. 9, 2016, 9:07 AM | 18 Comments
  • Sep. 7, 2016, 10:04 AM
    • CytRx (CYTR +2%) reaches its enrollment target of 132 patients in its Phase 2b clinical trial assessing lead product candidate aldoxorubicin in treatment-experienced patients with small cell lung cancer (SCLC).
    • The open-label study involves patients with metastatic SCLC who either failed to respond or progressed after treatment with one systemic therapy. Participants have received either 230 mg/m2 of aldoxorubicin or a standard dose of the chemo agent topotecan. The primary endpoint is progression-free survival (PFS) at Month 24. Overall survival is a secondary endpoint. According to ClinicalTrials.gov, the estimated study completion date is July 2017, but this needs revising since the completion should be September 2018 based on two-year PFS data.
    • The value proposition of aldoxorubicin is greater efficacy compared to doxorubicin by virtue of its linker molecule that binds to albumin. This supposedly drives greater uptake in the tumor which enables higher dosing without the collateral damage to healthy tissue.
    • Results from a recent Phase 3 study in soft tissue sarcoma failed to demonstrate a significant difference in PFS between aldoxorubicin and investigator's choice of therapy.
    • Previously: CytRx's lead product candidate shows mixed results in late-stage study; shares plummet 56% after hours (July 11)
    Sep. 7, 2016, 10:04 AM | 37 Comments
  • Jul. 29, 2016, 9:19 AM
    • CytRx (NASDAQ:CYTR): Q2 EPS of -$0.27 misses by $0.08.
    • Revenue of $0.1M
    • Shares +2.02% PM.
    Jul. 29, 2016, 9:19 AM | 5 Comments
  • Jul. 14, 2016, 7:01 PM
    • Nano cap CytRx (NASDAQ:CYTR) slumps 22% after hours on robust volume in response to its announcement of a proposed equity offering of stock and one-year warrants. Prices, volumes and terms have yet to be announced.
    • Net proceeds will fund working capital and general corporate purposes.
    • Update: On July 15, the company announced that the offering is 28.6M shares of common stock at $0.70 per share plus immediately exercisable one-year warrants to purchase up to 28.6M shares of stock at $0.70. Closing date is July 20.
    Jul. 14, 2016, 7:01 PM | 26 Comments
  • Jul. 12, 2016, 12:46 PM
    Jul. 12, 2016, 12:46 PM | 3 Comments
  • Jul. 12, 2016, 11:01 AM
    Jul. 12, 2016, 11:01 AM
  • Jul. 12, 2016, 9:24 AM
    Jul. 12, 2016, 9:24 AM
  • Jul. 11, 2016, 4:31 PM
    • Micro cap CytRx (NASDAQ:CYTR) craters 56% after hours on increased volume in response to its announcement of results from a Phase 3 clinical trial assessing lead product candidate aldoxorubicin compared to investigator's choice of therapy in patients with relapsed/refractory soft tissue sarcoma (STS).
    • The primary endpoint was progression-free survival (PFS) at month 24, which the study failed to show a significant difference between aldoxorubicin and investigator's choice of therapy (4.17 months versus 4.04 months). According to the company, the analysis did not provide for sufficient follow-up for nearly 2/3 of patients who entered the Phase 3 study after the partial clinical hold was resolved and enrollment resumed. The partial hold was instituted by the FDA in November 2014 after a patient died who received aldoxorubicin. The net result was almost 50% of all study participants were excluded from the PFS evaluation. The company expects to conduct a second analysis that will include longer follow-up data in Q4. It also intends to hold an end-of-Phase 3 meeting with the FDA to review the results.
    • On the plus side, objective response rate and disease control rate both favored aldoxorubicin over investigator's choice, including patients previously treated with doxorubicin.
    • Updated results will be presented at an upcoming medical conference.
    • Management will host a conference call today at 5:00 pm ET to discuss the results.
    • Previously: CytRx off premarket in response to FDA hold on aldoxorubicin trials (Nov. 18, 2014)
    Jul. 11, 2016, 4:31 PM | 45 Comments
  • May 31, 2016, 11:00 AM
    May 31, 2016, 11:00 AM | 6 Comments
  • May 11, 2016, 12:53 AM
    • CytRx (NASDAQ:CYTR): Q1 EPS of -$0.19 beats by $0.07.
    May 11, 2016, 12:53 AM
  • May 10, 2016, 9:16 AM
    May 10, 2016, 9:16 AM | 1 Comment
  • May 10, 2016, 9:06 AM
    • Micro cap CytRx (NASDAQ:CYTR) slumps 8% premarket on increased volume in response to a report published this morning by TheStreet's Adam Feuerstein. He says the company's Phase 3 clinical trial assessing lead product candidate aldoxorubicin for the second-line treatment of soft tissue sarcoma (STS) will likely fail considering its similarity to doxorubicin, an older chemo drug that doesn't work well against STS. The release of top-line data is expected next month.
    • The bulk of Mr. Feuerstein's pessimism is based on his take of an earlier Phase 2b study that showed treatment with aldoxorubicin doubled progression-free survival compared to doxorubicin. On closer inspection, however, the difference appeared to be due to the early termination of doxorubicin in sarcoma patients which reduced PFS and response rate to lower-than-expected levels. PFS for aldoxorubicin was comparable to earlier studies of doxorubicin so had patients been maintained on therapy, the difference in PFS would likely have been modest, certainly shy of statistical significance.
    • He also cites Ziopharm's (NASDAQ:ZIOP) failure with palifosfamide and Threshold Pharmaceuticals' (NASDAQ:THLD) failure with a similar compound called evofosfamide.
    • The value proposition of aldoxorubicin is greater efficacy compared to doxorubicin by virtue of its linker molecule that binds to albumin. This supposedly drives greater uptake in the tumor which enables higher dosing without the collateral damage to healthy tissue.
    • Previously: CytRx hits target number of progression events in late-stage aldoxorubicin study in soft tissue cancer; shares up 14% (April 4)
    May 10, 2016, 9:06 AM | 30 Comments